Emory University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).

1,208 total trials 208 currently recruiting 767 completed early-phase tilt top decile by trial count

Emory University: 1,208 sponsored US clinical trials, 208 recruiting.

Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.

Top-decile sponsor footprint

Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 47/100

767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,208 total, page 19 of 25

COMPLETED NA

Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women

NCT01147497

COMPLETED Phase 2

Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study

NCT01114373

COMPLETED Phase 2

Alteration in Timing of Plerixafor Administration

NCT01149863

TERMINATED Phase 2

Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer

NCT01194869

TERMINATED NA

Compassion Meditation and ReliefLink App for Suicidal, Low-Income, African Americans

NCT03463980

COMPLETED

Diabetes in the Elderly: Retrospective Study

NCT01104168

TERMINATED Phase 3

Prevention of Cystic Fibrosis Diabetes

NCT00967798

COMPLETED NA

A Culturally Tailored Lifestyle Intervention to Prevent Diabetes in South Asians

NCT01084928

COMPLETED Phase 4

Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients

NCT01027897

COMPLETED Phase 3

The Health Outcomes Management and Evaluation (HOME) Study

NCT01228032

COMPLETED Phase 2

Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study

NCT01114360

COMPLETED Phase 1

Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck

NCT01116336

COMPLETED Phase 2

Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection

NCT01095757

COMPLETED NA

A Web-based Bystander Education Program

NCT01903876

COMPLETED Phase 2

Glutamine Supplementation in Cystic Fibrosis

NCT01051999

COMPLETED

Pilot Study Assessing Oxidative Stress in Children

NCT01052207

COMPLETED Phase 4

Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques

NCT01230892

COMPLETED Phase 1

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

NCT01038388

COMPLETED NA

Caregiver Stress: Interventions to Promote Health and Wellbeing

NCT01188070

COMPLETED

A Pilot Study of Thrombin Generation Changes in Neonates Undergoing Placement of a Blalock-Taussig Shunt

NCT01340378

COMPLETED Phase 1

Trial on Safety and Pharmacokinetics of Intravaginal Curcumin

NCT01035580

COMPLETED

TT-CMV Observational Birth Cohort Study

NCT00907686

TERMINATED Phase 4

Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder

NCT00746421

COMPLETED Phase 4

Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells

NCT01041287

COMPLETED Phase 2

Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder

NCT01018992

COMPLETED Phase 4

The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension

NCT01049009

COMPLETED

Study of the Function of Cells Involved in Inflammation in the Lungs of Those With Acute Lung Injury and Sepsis

NCT01725061

COMPLETED

Comparison of Infection Rates Among Patients Using Two Catheter Access Devices

NCT00965198

COMPLETED

Diabetes Group Visits

NCT01000363

COMPLETED NA

Preventing Depression in People With Epilepsy: an Extension of Project UPLIFT

NCT01941706

COMPLETED Phase 3

Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females

NCT00813319

COMPLETED NA

Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer

NCT01271738

COMPLETED NA

Cost Effectiveness and Quality of Life in Heart Failure Patients With Diabetes

NCT01606085

COMPLETED Phase 2

Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease

NCT01041417

COMPLETED

Surgical Planning for Reconstruction of Complex Heart Defects

NCT00972608

COMPLETED

Magnetic Resonance Imaging (MRI) to Evaluate Brain Injury in Congenital Heart Disease

NCT00932633

COMPLETED Phase 2

Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers

NCT00941330

COMPLETED

Thiazolidinediones (TZD) Bone Loss and the Effects on Bone Marrow Differentiation and Osteoblast Formation

NCT00663143

COMPLETED NA

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

NCT02406586

COMPLETED Phase 2

Melatonin and the Metabolic Syndrome

NCT01038921

COMPLETED

Chemotherapy Monitoring With Breast Computed Tomography (CT)

NCT00808041

COMPLETED Phase 4

Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder

NCT01681849

COMPLETED

Comparison Study of Breast Computed Tomography (CT) With Magnetic Resonance Imaging (MRI)

NCT00957099

COMPLETED NA

Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer

NCT01526486

COMPLETED NA

Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis

NCT01188083

COMPLETED

An Evaluation of Psychological Parameters That May Influence the Outcome Following Arthroscopy and Arthroplasty for Temporomandibular Joint Surgery

NCT01396694

COMPLETED Phase 2

Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer

NCT00912340

COMPLETED

Breast Computed Tomography (CT) as a Diagnostic Tool

NCT00957307

COMPLETED Phase 1

Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule

NCT01502670

COMPLETED NA

FFA Hypertension and Inflammation in Lean and Obese Subjects

NCT00721617

← Previous Page 19 of 25 Next →

Phase Distribution

PhaseTrial count
Phase 1 154
Phase 2 190
Phase 3 36
Phase 4 134

What is open in the Emory University pipeline

208 recruiting of 1,208 indexed (17% open); 767 completed (63%).

Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).

Top condition: Depression (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Emory University: open-pipeline peers nationwide

Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 12%14%16%18%20% Total trials Recruiting share Emory UniversityNorthwestern UniversityUniversity of PittsburghNYU Langone HealthUniversity of Alabama at BirminghamBaylor Research InstituteNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Hunter College of City University of New YorkOchsner Health System
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,208 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Emory University page

1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.

  • 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Emory University pipeline card: 1,208 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.